Anjuli Singh: Registration is open for the 3rd ADC Toxicity Summit
Anjuli Singh, Program Director at Hanson Wade Group, posted on LinkedIn:
“ADC Toxicity: The Greatest Hurdle to Clinical Success…
Antibody-drug conjugates (ADCs) hold incredible potential – but overcoming toxicity remains the biggest challenge. From improving the translation of in vitro and in vivo studies to optimizing dose regimens and navigating regulatory requirements for preclinical models, the industry is racing to make ADCs safer and more effective.
That’s why the 3rd ADC Toxicity Summit is back as the only conference dedicated to advancing prediction and translation of ADC toxicities.
Covering key toxicities such as ocular, lung, liver, cardiovascular, and neuronal toxicity – gain invaluable insights from leading safety, preclinical, and clinical perspectives to bridge the multidisciplinary gap of toxicities and prediction of toxicities.
Covering key topics including:
- Improving in vitro models and applying AI & computational modelling for predicting toxicity – featuring John Oh-Joon Kwon (AstraZeneca)
- Enhancing in vivo model translation with insights on rodent and NHP studies – Ronnie Yeager (AbbVie) and Jennifer Brown (MacroGenics)
- Optimizing ADC design and ADME characterization to minimize toxicity – Bob Lutz (Iksuda) and Raymond Evers (Johnson and Johnson)
- Navigating ADC toxicity while prioritizing patient needs – Paolo Tarantino (DFCI) and Funda Meric-Bernstam (MD Anderson)
This is your chance to connect, collaborate, and drive real change in ADC development.
Find more information on developing safer, more tolerable ADCs here.
Or access all attendance opportunities here.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023